Pacer Advisors Inc. Purchases 4,433 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Pacer Advisors Inc. boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,985 shares of the biopharmaceutical company’s stock after purchasing an additional 4,433 shares during the quarter. Pacer Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $4,014,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ALXN. Nuveen Asset Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 57,650.8% during the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after acquiring an additional 3,630,846 shares in the last quarter. FMR LLC increased its holdings in shares of Alexion Pharmaceuticals by 10.4% during the first quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock valued at $3,939,729,000 after acquiring an additional 2,746,055 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Alexion Pharmaceuticals by 104.9% during the second quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after acquiring an additional 840,742 shares in the last quarter. Swedbank boosted its position in Alexion Pharmaceuticals by 95.5% in the second quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after buying an additional 698,096 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its position in Alexion Pharmaceuticals by 12.9% in the first quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock valued at $785,400,000 after buying an additional 665,574 shares during the last quarter. Institutional investors and hedge funds own 93.13% of the company’s stock.

Shares of ALXN stock opened at $99.25 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The company has a market cap of $22.25 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 0.90 and a beta of 1.67. The stock has a 50 day simple moving average of $103.91 and a 200-day simple moving average of $120.01. Alexion Pharmaceuticals, Inc. has a 1-year low of $92.56 and a 1-year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The business’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.07 EPS. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.05 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on ALXN shares. ValuEngine upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Royal Bank of Canada reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. Raymond James set a $168.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 30th. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, August 15th. Finally, Piper Jaffray Companies set a $180.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $159.76.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What is basic economics?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.